Comparative Pharmacology
Head-to-head clinical analysis: CAPRELSA versus NILOTINIB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPRELSA versus NILOTINIB.
CAPRELSA vs NILOTINIB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits multiple receptor tyrosine kinases involved in tumor angiogenesis and oncogenesis, including VEGFR2, EGFR, and RET.
Tyrosine kinase inhibitor targeting BCR-ABL, c-KIT, and PDGFR. Binds to inactive conformation of ABL kinase, preventing ATP binding and substrate phosphorylation.
300 mg orally once daily, with or without food.
300 mg orally twice daily for newly diagnosed chronic phase CML; 400 mg orally twice daily for resistant or intolerant CML. Take on an empty stomach (no food for 2 hours before and 1 hour after).
None Documented
None Documented
Terminal half-life approximately 90 hours (range 30–150 hours), supporting once-daily dosing; steady-state achieved by day 15.
Clinical Note
moderateNilotinib + Digoxin
"Nilotinib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateNilotinib + Digitoxin
"Nilotinib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateNilotinib + Deslanoside
"Nilotinib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateNilotinib + Acetyldigitoxin
"Nilotinib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life approximately 17 hours (range 14-20 hours), supporting twice-daily dosing.
Primarily fecal (approximately 75% of administered dose, mainly as unchanged drug and metabolites); renal excretion accounts for about 25% (less than 1% unchanged).
Primarily fecal (93% of absorbed dose) via biliary excretion; renal excretion accounts for <1% of unchanged drug.
Category C
Category D/X
Kinase Inhibitor
Kinase Inhibitor